The present invention relates to an antiseptic cap, and more particularly, to an antiseptic dead-end cap for a medical connector.
Catheters are widely used to treat patients requiring a variety of medical procedures. Catheters can either be acute, or temporary, for short-term use or chronic for long-term treatment. Catheters are commonly introduced into central veins (such as the vena cava) from peripheral vein sites to provide access to a patient's vascular system.
In an IV dispensing system, a luer connector, e.g., a male luer connector, can have a first end and a second end. The first end of the male luer connector can be connected to a fluid line that is connected to a fluid source, such as an IV bag filled with fluid. The second end of the male luer connector can be removably attached to a first end of a female needleless luer connector. The second end of the female needleless luer connector can be attached to a catheter that has been introduced into a patient.
When the male luer connector and the female needleless luer connector are attached to each other, fluid from the IV bag can flow into the patient. These connectors are often separated from each other at various times, for example, when a patient needs to use restroom facilities. When the connectors are disengaged from each other, the connectors are exposed and are prone to contamination. Current procedures to reduce contamination of the connectors involve swabbing the connectors with a disinfection. These procedures are prone to human error and are often not implemented. Furthermore, when a male luer connector is disengaged from a female needleless connector, there is no standard manner in which to store and protect the male luer connector until it is reattached to the female connector.
The present invention relates to an antiseptic dead-end cap for use with a connector that includes a base having first and second sides, a first annular wall extending from the first side of the base, a cylindrical center plug extending from the first side of the base, and a second annular wall extending from the second side of the base. The first annular wall has an outer surface and an inner surface. The cylindrical center plug has an outer surface and an inner surface, and is positioned within the first annular wall to form an annular chamber. The second annular wall has an outer surface and an inner surface, and defines a second chamber having an open end. An antiseptic material is on at least one of the inner surface of the first annular wall, the inner surface of the second annular wall, the outer surface of the second annular wall, and the outer surface of the cylindrical center plug.
The present invention further relates to an antiseptic dead-end cap for use with a connector that includes a base having first and second sides, a male connector portion extending from the first side of the base and configured to be connectable to a female luer, and a female connector portion extending from the second side of the base and configured to be connectable to a male luer. An antiseptic material is on at least a portion of the male luer connector portion or the female luer connector portion.
In some aspects, the male connector portion includes a first annular wall extending from the first side of the base and having an outer surface and an inner surface, and a cylindrical center plug extending from the first side of the base. The cylindrical center plug has an outer surface and an inner surface, and is positioned within the first annular wall to form an annular chamber. In such aspects, the female connector portion includes a second annular wall extending from the second side of the base, has an outer surface and an inner surface, and defines a second chamber having an open end.
In some aspects, the antiseptic material is a metal, while in other aspects, the antiseptic material can be an alcohol.
In other aspects, the first annular wall includes one or more threads. In still another aspect, the second annular wall includes one or more threads.
In yet another aspect, the antiseptic material is formed in at least one of the inner surface of the first annular wall, the inner surface of the second annular wall, the outer surface of the second annular wall, and the outer surface of the cylindrical center plug.
For a more complete understanding of the present invention, reference is made to the following Detailed Description of the Invention, considered in conjunction with the accompanying drawings, in which:
The present invention relates to an antiseptic cap assembly that engages a male end of a luer connector. It should be understood, however, that the teachings herein can be used with other types of medical connectors.
The antiseptic cap assembly 10 includes a cap holder 28 and a cap 30 sized to be positioned within the cap holder 28. The cap 30 includes a base 32 and an annular threaded portion 34 extending from the base 32. The base 32 could include a substantially flat surface 36 and an outer flange 38.
The threaded portion 34 of the cap 30 includes a rim 40 that defines an open end 42 (see
The configuration of the cap 30 is shown in perspective in
The cap 30 could be made from an absorbent material. The cap 30 could be made from porous plastic, for example, a medical grade sintered porous plastic material which is available from Porex Corporation, based in Fairburn, Ga. Other suitable manufacturers of the porous plastic material include Filtrona, Genpore, and Thermopore. It is desirable that the material can absorb and retain a fluid such as an antiseptic fluid. It is also desirable that the material is sufficiently rigid to maintain its structure. It is also desirable that the material is compressible and that the absorbed fluid is released on compression. The porous plastic material could be made of any suitable polymer, such as polyethylene, polypropylene, nylon, etc.
The use of the porous plastic material is only exemplary. It will be understood that the cap 30 could be made from any other suitable material, such as bonded fiber, cotton, silicone, urethane, polyester, cellulose, etc. The material could be natural or synthetic.
The threaded portion 34 of the cap 30 could be coated or impregnated with an antiseptic fluid, an anticoagulant fluid, and/or an antimicrobial fluid. An example of a suitable antiseptic fluid is isopropyl alcohol. The concentration of the isopropyl alcohol could vary, and is preferably 70, v/v. The concentration of alcohol could be in a range from 20, to 100%/o. It will be understand that other materials could be used, such as other alcohols, including ethanol, propanol, and/or butanol, or iodine, hydrogen peroxide, chlorhexidine gluconate, chlorhexidine acetate, etc. The antiseptic, anticoagulant, and/or antimicrobial agent could be in liquid or solid form.
The cap holder 28 includes a cylindrically shaped sidewall 52 that defines a chamber 54 sized to receive the cap 30 and accommodate the male luer 22. The cap holder 28 could include an outer flange 56 that protrudes radially outwardly from a distal end 58 of the sidewall 52. The outer flange 56 defines an open end 60. The cap holder 28 could include a substantially flat surface 62 that defines the opposite, closed end. The cap holder 28 could be made from a thermoplastic elastomer, such as the thermoplastic elastomer sold by ExxonMobil under the trademark SANTOPRENE, or any other suitable material. The cap holder 28 could be made from a more rigid material, such as a high-density polyethylene. The cap holder 28 and the cap 30 could be bonded to each other, or attached to each other by any suitable method, such as by adhesive or by molding.
When the cap 30 is attached to the cap holder 28, a gap 64 may exist between the flange 38 of the cap 30 and the cap holder 28, and between the threaded portion 34 of the cap 30 and the cap holder 28. Also, the cap 30 is attached to the cap holder 28 such that the cap 30 rotates conjointly with the cap holder 28.
As shown in
Generally, the cap 30 may be hydrophobic. However, because the hydrophobic material could serve to inhibit or minimize an antiseptic fluid, such as isopropyl alcohol, from passing through the cap 30, it may be desirable to make at least a portion of the cap 30 hydrophilic. For example, it may be desirable to treat at least a portion of the cap 30 with a hydrophilic surfactant. In this manner, the hydrophilic portion could allow the alcohol to pass therethrough, whereas the hydrophobic portion could serve to inhibit or minimize an antiseptic fluid, such as isopropyl alcohol, from passing therethrough. In one embodiment, the threaded portion 34 could be treated with a hydrophilic surfactant whereas the base 32 could remain hydrophobic, so as to be resistant to an antiseptic fluid, such as alcohol. The hydrophobic section could also act as a plug to prevent IV fluid from leaking through the tubing to go past the cap 30.
Referring to
The cap holder 28 could be configured to remain on the cap 30 after the antiseptic cap assembly 10 engages the luer connector 12. Alternatively, the cap holder 28 could be configured to be removably attached to the cap 30. For example, the cap holder 28 could be removed from the cap 30 after the antiseptic cap assembly 10 engages the luer connector 12.
Cap 130 includes an annular sidewall 111 extending from an outer flange 138 and substantially concentric with the threaded portion 134. When the cap holder 128 is used, the annular sidewall 111 is positioned proximate an outer surface of the cap holder 12. When the antiseptic cap assembly 110 is attached to the luer connector 12, the annular sidewall 111 bears against the outer surface of the threaded portion 18 of the luer connector 12. The annular sidewall 111 can be made from porous plastic like the remainder of the cap 130 or any other suitable material. The annular sidewall 111 covers and protects the outer surface of the threaded portion 18 of the luer connector 12. The annular sidewall Ill may contain antiseptic fluid and release at least a portion of an antiseptic fluid.
Cap 230 includes a center insert 211 that is integrally connected therewith. Alternatively, the cap 230 and the center insert 211 could be separate components. The center insert 211 may be made from porous plastic like the remainder of the cap 230 or any other suitable material, and may contain antiseptic fluid and release at least a portion of an antiseptic fluid. The center insert 211 could be treated with a hydrophilic surfactant, or otherwise made hydrophilic.
The center insert 211 protrudes from a base 232 of the cap 230 and is positioned within a threaded portion 234 of the cap 230. The center insert 211 has a distal end 213 that may have angled edges 215, thereby giving the center insert 211 a generally trapezoidal shape. The center insert 211 could define other shapes such as conical, square, rectangle, etc.
When the cap 230 is attached to a luer connector 12, the center insert 211 is positioned within the opening 24 formed in the male luer 22 and allows the antiseptic fluid to enter the male luer 22 to apply the antiseptic fluid to the inner tip 26 of the male luer 22.
A sealing mechanism, such as a center plug 311, is sized to extend from a base 332 of the cap 330 and is sized to be positioned within the threaded portion 334 of the cap 330. The cap 330 and the center plug 311 could be separate components as shown or, alternatively, the cap 330 and the center plug 311 could be integrally formed. Alternatively, the center plug 311 could be an extension of the cap holder 328 molded in.
The center plug 311 has a distal end 313 that may have angled edges 315, thereby giving the center plug 311 a generally trapezoidal shape. The center plug 311 could define other shapes such as conical, square, rectangle, etc.
The center plug 311 bears against the opening 24 formed in the male luer 22 to prevent the antiseptic fluid from entering the male luer 22. The center plug 311 extends a distance from the base 332 sufficient to engage the opening 24 in the male luer 22 before the threaded portion 334 of the cap 330 is compressed by the male luer 22, to seal the opening 24 in the male luer 22.
The center plug 311 could be made of a non-porous material, such as rubber, or any other suitable material. The center plug 311 could be made of porous plastic and left in a hydrophobic state, i.e., not treated with a surfactant like the threaded portion 334 of the cap 330, thereby inhibiting or minimizing antiseptic fluid from passing therethrough and into the opening 24 formed in the male luer 22. In this manner, the center plug 311 serves to limit or prevent alcohol from entering the fluid line 316 of the luer connector 312. Also the center plug 311 could act as a plug to prevent IV fluid from dripping out of the line.
The configuration of the sealing mechanism is only exemplary. It will be understood that the present invention could employ other sealing mechanisms. For example, the sealing mechanism could be a center pin (not shown) sized to extend further into the opening 24 formed in the male luer 22 than the center plug 311. The center plug 311 may extend past the threads on the threaded portion 324 and inserted prior to thread engagement.
The cap holder 428 includes an inner-facing flange 411 that may form a protective seal that closes off the interior of the cap holder 428 when the antiseptic cap assembly 410 is engaged to the luer connector 12. The inner flange 411 extends radially inward from a distal end 458 of the sidewall 452 of the cap holder 428. When the antiseptic cap assembly 410 is engaged to the luer connector 12, the inner-facing flange 411 of the cap holder 428 may contact the threaded portion 18 of the luer connector 12 to seal the interior of the cap holder 428.
The inner-facing flange 411 of the cap holder 428 may provide a physical barrier to the ingress of pathogens, dust or other contaminants into the cap holder 428. The inner-facing flange 411 may serve to retain at least a portion of the antiseptic fluid from the antiseptic cap assembly 410 from leaking out. The inner-facing flange 411 may prevent evaporation of at least a portion of the antiseptic fluid that is retained.
The configuration of the cap holder 428 could vary. For example, the cap holder 428 could include an outer flange (not shown), such as the outer flange 56 (
The antiseptic cap assembly 510 includes a center plug 511, such as the center plug 311 shown in
It should be understood that various features of various embodiments disclosed herein could be used together without departing from the spirit or scope of the present invention.
The cap 630 includes an annular portion 611 extending from a base 632. The annular portion 611 is configured without threads but is sized to engage the luer connector 12 with a push-on friction fit. The antiseptic cap assembly 610 could be removed by pulling out of the luer connector 12.
The annular portion 611 of the cap 630 could be configured such that the inner surface contacts the male luer 22 and is compressed by the male luer 22 to release antiseptic fluid when the cap 630 is pushed on to the male luer 22. The outer surface of the annular portion 611 could also contact against the inner threads 18 of the threaded portion 18 of the male luer 22 and could also release antiseptic fluid on this side. Alternatively, the annular portion 611 could be configured to avoid contact with the threads 20 of the luer connector 12. The annular portion 611 does not need to be tapered as shown.
The cap 730 includes an annular portion 711 extending from a base 732. The annular portion 711 is configured and sized to engage the luer connector 12 with a push-on friction fit.
The antiseptic chamber 715 is attached to the base 732 of the cap 730 and is formed by a continuous sidewall 713 and an end wall 723. The sidewall 713 includes an inner flange 717 that extends radially inward from the sidewall 713. The flange 717 defines an open end 721.
The base 732 of the cap 730 is keyed to the antiseptic chamber 715. The base 732 of the cap 730 is positioned within the antiseptic chamber 715 such that the outer flange 738 of the base 732 is captured in the antiseptic chamber 715 by the inner flange 717 of the antiseptic chamber 715 which extends over the base 732. The base 732 closes off the disinfectant chamber 715 and the annular portion 711 of the cap 730 is in contact with the inner flange 717 of the antiseptic chamber 715. The cap 730 could be attached to the antiseptic chamber 715 such that the cap 730 rotates conjointly with the antiseptic chamber 715. In one embodiment, the base 732 of the cap 730 does not need to be keyed to the antiseptic chamber 715 in a push-on design.
The antiseptic chamber 715 can include an absorbent material 725, such as a pad, sponge, or elastomeric foam, configured to retain an antiseptic fluid. The absorbent material 725 could be wetted or soaked with the antiseptic fluid. The absorbent material 725 could be deformable. The cap 730 could be made from a porous plastic material that serves as a carrier for the transfer of antiseptic fluid from the disinfectant chamber 715. When the cap holder 728 is compressed, the absorbent material 725 releases at least a portion of the antiseptic fluid. The fluid can then flow through the base 732 and along the annular portion 711 to be delivered to the male luer 22.
It will be understood that the present invention could employ other mechanisms that involve pushing on a component of an antiseptic cap assembly to activate or release the antiseptic fluid.
The cap 830 includes an annular portion 811 extending from a base 832. The annular portion 811 is configured without threads and sized to engage the luer connector 12 with a push-on friction fit. The antiseptic cap assembly 810 could be removed by pulling out of the luer connector 12.
The cap holder 828 includes retainers 813 that serve to retain or secure the cap 830 on the luer connector 12. The retainers 813 include a pair of shoulders 815, 817 that extend perpendicularly from opposite sides of the outer flange 856 of the cap holder 828 and a pair of arms 823, 825 that extend radially inward from the shoulders 815, 817.
When the antiseptic cap assembly 810 is engaged to the luer connector 12, the arms 823, 825 of the retainers 813 extend over the male luer 22 to retain the cap 830. The retainers 813 could be made from a thermoplastic elastomer, such as SANTOPRENE, or any other suitable material. The retainers 813 could be made from a flexible material.
The cap holder 828 may include gripping areas defined by a recessed portion 827 (
The cap 930 includes a base 932 and an annular threaded portion 934 extending from the base 932. The base 932 includes an outer flange 938 with a plurality of teeth 911 (see
The cap holder 928 includes a retaining mechanism for retaining the cap 930 in the cap holder 928. The retaining mechanism could include a first protrusion 913 that extends from one section of the sidewall 952 of the cap holder 928, and a second protrusion 915 that extends from an opposite section of the sidewall 952 of the cap holder 928. The first and second protrusions 913, 915 are configured to extend over the base 932 of the cap 930. Alternatively, the retaining mechanism could include a single ring around the interior of the cap holder 928.
The cap holder 928 includes a plurality of teeth 917 that mate with the teeth 911 to form a ratchet mechanism. The teeth 917 interact with the teeth 911 to allow the cap 930 to rotate in the cap holder 928 in only one direction, and have angled faces 916 and generally perpendicular faces 918, like the teeth 911 of the base 932. Alternatively, it could be configured to allow for rotation in both directions.
The ratchet mechanism provides an audible or a tactile feedback to indicate that the antiseptic cap assembly 910 is properly secured. Also, the ratchet mechanism could limit torque to prevent damage to the luer connector 12 or to the cap 930. The cap 930 is threaded on the male luer 22 in accordance with other embodiments of the cap 930. If the cap 930 is turned beyond the limit of the threads, instead of damaging the male luer 22, the cap 930 will slide with respect to the cap holder 928, the angled teeth 911, 917 of the base 932 of the cap 930 and the cap holder 930 respectively sliding past one another to prevent further tightening of the cap 930 onto the male luer 22. When removing the cap 930 from the male luer 22, the generally perpendicular faces 914, 918 engage and do not permit sliding.
The cap 1030 is used without a cap holder. The cap 1030 includes a base 1032 and an annular threaded portion 1034 extending from the base 1032. Antiseptic fluid can be associated with the interior surface of the annular threaded portion 1034.
The configuration of the cap 1030 is only exemplary. For example, the cap 1030 could be configured without threads and sized to engage the luer connector 12 with a push-on friction fit. Likewise, the cap 1030 could also include a sidewall, like that shown in
At least a portion of the cap 1130 could be treated with a hydrophilic surfactant, or otherwise made hydrophilic. The threaded portion 1134 could be treated with a hydrophilic surfactant whereas the base 1132 could remain hydrophobic, so as to be resistant to and non-absorbent of an antiseptic fluid.
A center plug 1111 could bear against the opening 24 formed in the male luer 22 to prevent the antiseptic fluid from entering the male luer 22. The center plug 1111 could be made of porous plastic and left in a hydrophobic state, thereby inhibiting or minimizing antiseptic fluid from passing therethrough and into the opening 24 formed in the male luer 22. The hydrophobic section could also act as a plug in the IV line to prevent ingress of antiseptic fluid or to stop leakage of IV fluid.
The cap holder 1228 has a notch 1211 in an outer flange 1256 that is configured to attached to a supporting surface, such as a fluid line 1213. As shown, the cap holder 1228 has a plurality of ribs 1215 extending along a sidewall 1252 from one end 1217 of the cap holder 1228 to the opposite end 1219 of the cap holder 1228. The ribs 1215 facilitate gripping of the cap holder 1228.
A sealing mechanism, such as a center plug 1311, is sized to extend from the cap holder 1328 through the base 1332 and is sized to be positioned within the threaded portion 1334 of the cap 1330. As such, the center plug 1311 is made of a non-porous material such as SANTOPRENE, or any other suitable material. In particular, the center plug 1311 includes an arm 1313 with one end 1315 extending from the base 1332, and a sphere 1317 attached to an opposite end 1319 of the arm 1313. The sphere 1317 is configured to bear against the opening 24 formed in the male luer 22 to limit the distance that the antiseptic fluid can travel into the male luer 22. Alternatively, the center plug 1311 could extend from the base 1332 and be made of another material such as rubber. The sphere 1317 could be replaced with a non-spherical device.
Any of the antiseptic cap assemblies 10, 110, 210, 310, 410, 510, 610, 710, 810, 910, 1010, 1110, 1210, and 1310 disclosed herein could be configured to be removably attached to a suitable surface (not shown), such as a IV bag, IV pump, or IV pole, etc., for use. For example, in
In
In
Alternative fastening mechanisms could be provided. For example, the antiseptic cap assembly could include a ring (not shown).
The antiseptic cap assembly could be incorporated in kits with flush syringes, caps for treating a catheter or needleless connector, and line access devices, etc. The antiseptic fluid used could include an anticoagulant material, and/or an antimicrobial material. Examples of antiseptic fluid that could be used are disclosed in U.S. patent application Ser. No. 11/821,190, filed on Jun. 22, 2007, and Ser. No. 12/214,526, filed on Jun. 19, 2008. The entire disclosures of U.S. patent application Ser. Nos. 11/821,190 and 12/214,526 are incorporated herein by reference in their entirety.
As shown in
The first annular wall 1416 defines an open end 1422. The base 1418 closes the opposite end of the first annular wall 1416. A cylindrical center plug 1430 extends from the base 1418 in the direction of the first annular wall 1416 and is closed by an end wall 1432. The first annular wall 1416 and the cylindrical center plug 1430 are coaxial with one another and the cylindrical center plug 1430 is smaller in diameter than the first annular wall 1416. The first annular wall 1416, the base 1418, and the cylindrical center plug 1430 define a first chamber 1424 that is annular, accessible by the open end 1422, and sized to receive the female luer. When a female luer is inserted through the open end 1422 of the first portion 1412, the cylindrical center plug 1430 and the end wall 1432 are inserted into a portion of the female luer.
The second portion 1414 includes a second annular wall 1426 extending from the base 1418 opposite the direction of the first annular wall 1416, and forms an internal shoulder 1428 with the base 1418. The second annular wall 1426 has an open end 1434 and forms a second chamber 1436, while the cylindrical center plug 1430 and the end wall 1432 form a third chamber 1438. The second chamber 1436 and the third chamber 1438 are in fluidic communication, and the second chamber 1436 is accessible by the open end 1434. The second chamber 1436 is sized to receive a male luer.
One or more threads 1440 are positioned on an exterior wall of the second annular wall 1426. The threads 1440 are configured to engage and cooperate with threads of a male luer connector, such as luer connector 12 shown in
Using the male luer connector 12 shown in
As mentioned above, the antiseptic dead-end cap 1410 has a dual operability wherein it is configured to not only attach to a male luer connector, but also a female luer connector. Generally, a female luer connector can include a circumferential wall that defines a chamber and has external threads. When attaching the dead-end cap 1410 to a female luer connector, the circumferential wall of the female luer connector is inserted through the open end 1422 and into the first chamber 1424, such that the cylindrical center plug 1420 is inserted into the circumferential wall of the female luer connector. The dead-end cap 1410 can be twisted so that the one or more threads 1420 engage the female luer connector, securing the dead-end cap 1410 with the female luer connector.
The dead-end cap 1410 functions to cap a male luer connector and/or a female luer connector so that fluid does not leak from a fluid source. The dead-end cap 1410 may be used for a temporary disconnect of male and female luers so that they do not warrant disposal.
While the antiseptic cap disclosed herein includes male and female connector portions, it could also be provided having just a male or just a female portion. In an arrangement where the antiseptic dead-end cap 1420 includes only a male connector portion, the dead-end cap 1420 could include the base 1418, the first annular wall 1416 extending from the base 1418, the cylindrical center plug 1430 extending from the base 1418 in the direction of the first annular wall 1416 and closed by the end wall 1432, and the plurality of threads 1420. The second annular wall 1426, and the female side of the cap can be eliminated. In an arrangement where the antiseptic dead-end cap 1420 includes only a female connector portion, the dead-end cap 1420 could include the base 1418, the second annular wall 1426 and the threads 1440, with the base 1418 and the second annular wall 1426 defining the second chamber 1436. The first annular wall 1416, and the cylindrical center plug 1430 could be eliminated.
Portions of the antiseptic dead-end cap 1410, such as an inner surface of the first annular wall 1416, the plurality of threads 1420, an outer surface of the second annular wall 1426, an inner surface of the second annular wall 1426, and the second portion threads 1440, could be coated or impregnated with an antiseptic fluid, an anticoagulant fluid, and/or an antimicrobial fluid. An example of a suitable antiseptic fluid is isopropyl alcohol. The concentration of the isopropyl alcohol could vary, and is preferably 70%. The concentration of alcohol could be in a range from 20% to 100%. It will be understand that other materials could be used, such as other alcohols, including ethanol, propanol, and/or butanol, or iodine, hydrogen peroxide, chlorhexidine gluconate, chlorhexidine acetate, etc. The antiseptic, anticoagulant, and/or antimicrobial agent could be in liquid or solid form.
The antiseptic dead-end cap 1410 may be constructed of a material having a 40-60 durometer hardness value on a Shore A scale. The material may be a medium soft to medium hard rubber that is plyable and malleable for purposes of engagement with a luer.
Antiseptic Coatings
It is contemplated that the devices described herein can be coated with an antiseptic coating by any suitable technique such as immersion of the part into an antiseptic solution, by spray coating the part with the antiseptic solution, by blending the antiseptic solution or material into the polymeric material used to fabricate the device.
A quantity of physiological, antimicrobial metal compound is added to the resin for direct molding of an article. Physiological, antimicrobial metals are meant to include the precious metals, such as silver, gold and platinum, and copper and zinc. Physiological, antimicrobial metal compounds used herein include oxides and salts of preferably silver and also gold, for example: silver acetate, silver benzoate, silver carbonate, silver citrate, silver chloride, silver iodide, silver nitrate, silver oxide, silver sulfa diazine, silver sulfate, gold chloride and gold oxide. Platinum compounds such as chloroplatinic acid or its salts (e.g., sodium and calcium chloroplatinate) may also be used. Also, compounds of copper and zinc may be used, for example: oxides and salts of copper and zinc such as those indicated above for silver. Single physiological, antimicrobial metal compounds or combinations of physiological, antimicrobial metal compounds may be used.
Preferred physiological, antimicrobial metal compounds used in this invention are silver acetate, silver oxide, silver sulfate, gold chloride and a combination of silver oxide and gold chloride. The particles of the silver compounds are sufficiently able to be extracted to form a zone of inhibition to prevent and kill bacteria growth.
In another preferred form of the invention the devices herein are impregnated with triclosan and silver compounds or triclosan and chlorhexidine, or chlorhexidine gluconate, or chlorhexidine acetate.
It will be understood that the embodiments described herein are merely exemplary and that a person skilled in the art may make many variations and modifications without departing from the spirit and scope of the invention. All such variations and modifications are intended to be included within the scope of the invention as defined by the appended claims.
This application is a continuation of U.S. patent application Ser. No. 13/803,289, filed on Mar. 14, 2013, which is a continuation-in-part of U.S. patent application Ser. No. 13/113,777, filed on May 23, 2011, now U.S. Pat. No. 9,867,975, the entire disclosure of each of which is expressly incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
382297 | Fry | May 1888 | A |
877946 | Overton | Feb 1908 | A |
1793068 | Dickinson | Feb 1931 | A |
2098340 | Henahan | Nov 1937 | A |
2436297 | Guarnaschelli | Feb 1948 | A |
2457052 | Le Clair | Dec 1948 | A |
2771644 | Martin | Nov 1956 | A |
3270743 | Gingras | Sep 1966 | A |
3301392 | Eddingfield | Jan 1967 | A |
3411665 | Blum | Nov 1968 | A |
3538950 | Porteners | Nov 1970 | A |
3604582 | Boudin | Sep 1971 | A |
3882858 | Klemm | May 1975 | A |
3977401 | Pike | Aug 1976 | A |
3987930 | Fuson | Oct 1976 | A |
4041934 | Genese | Aug 1977 | A |
4053052 | Jasper | Oct 1977 | A |
4095810 | Ku lie | Jun 1978 | A |
4133441 | Mittleman et al. | Jan 1979 | A |
4192443 | McLaren | Mar 1980 | A |
4243035 | Barrett | Jan 1981 | A |
4264664 | Kunz | Apr 1981 | A |
4280632 | Yuhara | Jul 1981 | A |
4294370 | Toeppen | Oct 1981 | A |
4317446 | Ambrosio et al. | Mar 1982 | A |
4335756 | Sharp et al. | Jun 1982 | A |
4354490 | Rogers | Oct 1982 | A |
4384589 | Morris | May 1983 | A |
4402691 | Rosenthal et al. | Sep 1983 | A |
4417890 | Dennehey et al. | Nov 1983 | A |
4427126 | Ostrowsky | Jan 1984 | A |
4432764 | Lopez | Feb 1984 | A |
4432766 | Bellotti et al. | Feb 1984 | A |
4439184 | Wheeler | Mar 1984 | A |
4440207 | Genatempo et al. | Apr 1984 | A |
4444310 | Odell | Apr 1984 | A |
4461368 | Plourde | Jul 1984 | A |
4480940 | Woodruff | Nov 1984 | A |
4507111 | Gordon et al. | Mar 1985 | A |
4624664 | Peluso et al. | Nov 1986 | A |
4666057 | Come et al. | May 1987 | A |
4666427 | Larsson et al. | May 1987 | A |
4671306 | Spector | Jun 1987 | A |
4703762 | Rathbone et al. | Nov 1987 | A |
4728075 | Paradis | Mar 1988 | A |
4728321 | Chen | Mar 1988 | A |
4747502 | Luenser | May 1988 | A |
4752983 | Crieshaber | Jun 1988 | A |
4778447 | Velde et al. | Oct 1988 | A |
4799926 | Haber | Jan 1989 | A |
4810241 | Rogers | Mar 1989 | A |
4811847 | Reif et al. | Mar 1989 | A |
4813933 | Turner | Mar 1989 | A |
4834271 | Litwin | May 1989 | A |
4927019 | Haber et al. | May 1990 | A |
4957637 | Cornell | Sep 1990 | A |
4983161 | Dadson et al. | Jan 1991 | A |
4989733 | Patry | Feb 1991 | A |
4991629 | Ernesto et al. | Feb 1991 | A |
5031622 | LaHaye | Jul 1991 | A |
5065783 | Ogle, II | Nov 1991 | A |
5143104 | Iba et al. | Sep 1992 | A |
5184742 | DeCaprio et al. | Feb 1993 | A |
5190534 | Kendell | Mar 1993 | A |
5195957 | Tollini | Mar 1993 | A |
5205821 | Kruger et al. | Apr 1993 | A |
5242421 | Chan | Sep 1993 | A |
5242425 | White et al. | Sep 1993 | A |
5246011 | Caillouette | Sep 1993 | A |
D342134 | Mongeon | Dec 1993 | S |
5352410 | Hansen et al. | Oct 1994 | A |
5471706 | Wallock et al. | Dec 1995 | A |
5496288 | Sweeney | Mar 1996 | A |
5536258 | Folden | Jul 1996 | A |
5552115 | Malchesky | Sep 1996 | A |
5554127 | Crouther et al. | Sep 1996 | A |
5554135 | Menyhay | Sep 1996 | A |
5580530 | Kowatsch et al. | Dec 1996 | A |
5613615 | Zeyfang et al. | Mar 1997 | A |
5620088 | Martin et al. | Apr 1997 | A |
5624402 | Imbert | Apr 1997 | A |
5688253 | Lundquist | Nov 1997 | A |
5694978 | Heilmann et al. | Dec 1997 | A |
5702017 | Goncalves | Dec 1997 | A |
5722537 | Sigler | Mar 1998 | A |
5776116 | Lopez | Jul 1998 | A |
5792120 | Menyhay | Aug 1998 | A |
5810792 | Fangrow, Jr. et al. | Sep 1998 | A |
5820604 | Fox et al. | Oct 1998 | A |
5827244 | Boettger | Oct 1998 | A |
5839715 | Leinsing | Nov 1998 | A |
5941857 | Nguyen et al. | Aug 1999 | A |
5951519 | Utterberg | Sep 1999 | A |
5954957 | Chin-Loy et al. | Sep 1999 | A |
5971972 | Rosenbaum | Oct 1999 | A |
D416086 | Parris et al. | Nov 1999 | S |
5989229 | Chiappetta | Nov 1999 | A |
6041805 | Gydesen et al. | Mar 2000 | A |
6045539 | Menyhay | Apr 2000 | A |
6068475 | Stoyka, Jr. et al. | May 2000 | A |
6095356 | Rits | Aug 2000 | A |
6116468 | Nilson | Sep 2000 | A |
6117114 | Paradis | Sep 2000 | A |
6126640 | Tucker et al. | Oct 2000 | A |
6152913 | Feith et al. | Nov 2000 | A |
6158614 | Haines et al. | Dec 2000 | A |
6170522 | Tanida | Jan 2001 | B1 |
6171287 | Lynn et al. | Jan 2001 | B1 |
6179141 | Nakamura | Jan 2001 | B1 |
6190364 | Imbert | Feb 2001 | B1 |
6202870 | Pearce | Mar 2001 | B1 |
6202901 | Gerber et al. | Mar 2001 | B1 |
6206134 | Stark et al. | Mar 2001 | B1 |
6227391 | King | May 2001 | B1 |
6245056 | Walker et al. | Jun 2001 | B1 |
6250315 | Ernster | Jun 2001 | B1 |
6315761 | Shcherbina et al. | Nov 2001 | B1 |
6394983 | Mayoral et al. | May 2002 | B1 |
6402207 | Segal et al. | Jun 2002 | B1 |
6550493 | Williamson et al. | Apr 2003 | B2 |
6555504 | Ayai et al. | Apr 2003 | B1 |
6585691 | Vitello | Jul 2003 | B1 |
6632199 | Tucker et al. | Oct 2003 | B1 |
6679395 | Pfefferkorn et al. | Jan 2004 | B1 |
6679870 | Finch et al. | Jan 2004 | B1 |
6681803 | Taneya et al. | Jan 2004 | B2 |
6685694 | Finch et al. | Feb 2004 | B2 |
6692468 | Waldenburg | Feb 2004 | B1 |
6716396 | Anderson | Apr 2004 | B1 |
6827766 | Carnes et al. | Dec 2004 | B2 |
6911025 | Miyahar | Jun 2005 | B2 |
6943035 | Davies et al. | Sep 2005 | B1 |
7056308 | Utterberg | Jun 2006 | B2 |
7083605 | Miyahara | Aug 2006 | B2 |
7160272 | Eyal et al. | Jan 2007 | B1 |
7198611 | Connell et al. | Apr 2007 | B2 |
7282186 | Lake, Jr. et al. | Oct 2007 | B2 |
7309326 | Fangrow, Jr. | Dec 2007 | B2 |
7316669 | Ranalletta | Jan 2008 | B2 |
7431712 | Kim | Oct 2008 | B2 |
7452349 | Miyahar | Nov 2008 | B2 |
7516846 | Hansen | Apr 2009 | B2 |
7614426 | Kitani et al. | Nov 2009 | B2 |
7635344 | Tennican et al. | Dec 2009 | B2 |
D607325 | Rogers et al. | Jan 2010 | S |
7708714 | Connell et al. | May 2010 | B2 |
7731678 | Tennican et al. | Jun 2010 | B2 |
7731679 | Tennican et al. | Jun 2010 | B2 |
7749189 | Tennican et al. | Jul 2010 | B2 |
7753891 | Tennican et al. | Jul 2010 | B2 |
7763006 | Tennican | Jul 2010 | B2 |
7766182 | Trent et al. | Aug 2010 | B2 |
7766897 | Ramsey et al. | Aug 2010 | B2 |
7776011 | Tennican et al. | Aug 2010 | B2 |
7780794 | Rogers et al. | Aug 2010 | B2 |
7794675 | Lynn | Sep 2010 | B2 |
7799010 | Tennican | Sep 2010 | B2 |
7815614 | Fangrow, Jr. | Oct 2010 | B2 |
7857793 | Raulerson et al. | Dec 2010 | B2 |
7922701 | Buchman | Apr 2011 | B2 |
7959026 | Bertani | Jun 2011 | B2 |
7985302 | Rogers et al. | Jul 2011 | B2 |
7993309 | Schweikert | Aug 2011 | B2 |
8065773 | Vaillancourt et al. | Nov 2011 | B2 |
8066670 | Cluff et al. | Nov 2011 | B2 |
8069523 | Vaillancourt et al. | Dec 2011 | B2 |
8113837 | Zegarelli | Feb 2012 | B2 |
8162899 | Tennican | Apr 2012 | B2 |
8167847 | Anderson et al. | May 2012 | B2 |
8172825 | Solomon et al. | May 2012 | B2 |
8206514 | Rogers et al. | Jun 2012 | B2 |
8231587 | Solomon et al. | Jul 2012 | B2 |
8231602 | Anderson et al. | Jul 2012 | B2 |
8262628 | Fangrow, Jr. | Sep 2012 | B2 |
8262643 | Tennican | Sep 2012 | B2 |
8273303 | Ferlic et al. | Sep 2012 | B2 |
8281824 | Molema et al. | Oct 2012 | B2 |
8328767 | Solomon et al. | Dec 2012 | B2 |
8336152 | Kerr et al. | Dec 2012 | B2 |
8343112 | Solomon et al. | Jan 2013 | B2 |
8361408 | Lynn | Jan 2013 | B2 |
8372045 | Needle et al. | Feb 2013 | B2 |
8377040 | Burkholz et al. | Feb 2013 | B2 |
8419713 | Solomon et al. | Apr 2013 | B1 |
8480968 | Lynn | Jul 2013 | B2 |
8523830 | Solomon et al. | Sep 2013 | B2 |
8523831 | Solomon et al. | Sep 2013 | B2 |
8533887 | Hirst | Sep 2013 | B2 |
8545479 | Kitani et al. | Oct 2013 | B2 |
8641681 | Solomon et al. | Feb 2014 | B2 |
8641684 | Utterberg et al. | Feb 2014 | B2 |
8647308 | Solomon et al. | Feb 2014 | B2 |
8647326 | Solomon et al. | Feb 2014 | B2 |
8671496 | Kerr et al. | Mar 2014 | B2 |
8740864 | Hoang et al. | Jun 2014 | B2 |
8777504 | Shaw et al. | Jul 2014 | B2 |
8845593 | Anderson et al. | Sep 2014 | B2 |
8910919 | Bonnal et al. | Dec 2014 | B2 |
8968268 | Anderson et al. | Mar 2015 | B2 |
8999073 | Rogers et al. | Apr 2015 | B2 |
9072296 | Mills et al. | Jul 2015 | B2 |
9078992 | Ziebol et al. | Jul 2015 | B2 |
9095667 | Von Schuckmann | Aug 2015 | B2 |
9101750 | Solomon et al. | Aug 2015 | B2 |
9114915 | Solomon et al. | Aug 2015 | B2 |
9125600 | Steube et al. | Sep 2015 | B2 |
9149624 | Lewis | Oct 2015 | B2 |
9180252 | Gelblum et al. | Nov 2015 | B2 |
9192449 | Kerr et al. | Nov 2015 | B2 |
9216440 | Ma et al. | Dec 2015 | B2 |
9242084 | Solomon et al. | Jan 2016 | B2 |
9259284 | Rogers et al. | Feb 2016 | B2 |
9259535 | Anderson et al. | Feb 2016 | B2 |
9283367 | Hoang et al. | Mar 2016 | B2 |
9283368 | Hoang et al. | Mar 2016 | B2 |
9283369 | Ma et al. | Mar 2016 | B2 |
9289588 | Chen | Mar 2016 | B2 |
9302049 | Tekeste | Apr 2016 | B2 |
9320858 | Grimm et al. | Apr 2016 | B2 |
9320859 | Grimm et al. | Apr 2016 | B2 |
9320860 | Grimm et al. | Apr 2016 | B2 |
9352140 | Kerr et al. | May 2016 | B2 |
9352141 | Wong | May 2016 | B2 |
9399125 | Burkholz | Jul 2016 | B2 |
9408971 | Carlyon | Aug 2016 | B2 |
9527660 | Tennican | Dec 2016 | B2 |
9592375 | Tennican | Mar 2017 | B2 |
9700676 | Anderson et al. | Jul 2017 | B2 |
9700677 | Anderson et al. | Jul 2017 | B2 |
9700710 | Anderson et al. | Jul 2017 | B2 |
9707348 | Anderson et al. | Jul 2017 | B2 |
9707349 | Anderson et al. | Jul 2017 | B2 |
9707350 | Anderson et al. | Jul 2017 | B2 |
9809355 | Solomon et al. | Nov 2017 | B2 |
9867975 | Gardner et al. | Jan 2018 | B2 |
9907617 | Rogers | Mar 2018 | B2 |
9933094 | Fangrow | Apr 2018 | B2 |
9999471 | Rogers et al. | Jun 2018 | B2 |
10016587 | Gardner et al. | Jul 2018 | B2 |
10046156 | Gardner | Aug 2018 | B2 |
10166381 | Gardner et al. | Jan 2019 | B2 |
20020010438 | Finch et al. | Jan 2002 | A1 |
20020193752 | Lynn | Dec 2002 | A1 |
20030060749 | Aneas | Mar 2003 | A1 |
20030062376 | Sears et al. | Apr 2003 | A1 |
20030153865 | Connell et al. | Aug 2003 | A1 |
20040034042 | Tsuji et al. | Feb 2004 | A1 |
20040048542 | Thomascheisky et al. | Mar 2004 | A1 |
20040052689 | Yao | Mar 2004 | A1 |
20040215148 | Hwang et al. | Oct 2004 | A1 |
20040258560 | Lake, Jr. et al. | Dec 2004 | A1 |
20050013836 | Raad | Jan 2005 | A1 |
20050065479 | Schiller et al. | Mar 2005 | A1 |
20050124970 | Kunin et al. | Jun 2005 | A1 |
20050147524 | Bousquet | Jul 2005 | A1 |
20050147525 | Bousquet | Jul 2005 | A1 |
20050148930 | Hseih et al. | Jul 2005 | A1 |
20050203460 | Kim | Sep 2005 | A1 |
20050214185 | Castaneda | Sep 2005 | A1 |
20060030827 | Raulerson et al. | Feb 2006 | A1 |
20060195117 | Rucker et al. | Aug 2006 | A1 |
20060261076 | Anderson | Nov 2006 | A1 |
20070112333 | Hoang et al. | May 2007 | A1 |
20070167910 | Tennican et al. | Jul 2007 | A1 |
20070187353 | Fox et al. | Aug 2007 | A1 |
20070249996 | Tennican et al. | Oct 2007 | A1 |
20070265578 | Tennican et al. | Nov 2007 | A1 |
20070282280 | Tennican | Dec 2007 | A1 |
20070287989 | Crawford et al. | Dec 2007 | A1 |
20080019889 | Rogers et al. | Jan 2008 | A1 |
20080027399 | Harding et al. | Jan 2008 | A1 |
20080033371 | Updegraff et al. | Feb 2008 | A1 |
20080039803 | Lynn | Feb 2008 | A1 |
20080058733 | Vogt et al. | Mar 2008 | A1 |
20080086091 | Anderson et al. | Apr 2008 | A1 |
20080093245 | Periasamy et al. | Apr 2008 | A1 |
20080095680 | Steffens et al. | Apr 2008 | A1 |
20080097315 | Miner et al. | Apr 2008 | A1 |
20080128646 | Clawson | Jun 2008 | A1 |
20080132880 | Buchman | Jun 2008 | A1 |
20080147047 | Davis et al. | Jun 2008 | A1 |
20080177250 | Howlett et al. | Jul 2008 | A1 |
20080235888 | Vaillancourt et al. | Oct 2008 | A1 |
20080287920 | Fangrow et al. | Nov 2008 | A1 |
20090008393 | Howlett et al. | Jan 2009 | A1 |
20090012426 | Tennican | Jan 2009 | A1 |
20090062766 | Howlett et al. | Mar 2009 | A1 |
20090093757 | Tennican | Apr 2009 | A1 |
20090099529 | Anderson et al. | Apr 2009 | A1 |
20090137969 | Colantonio et al. | May 2009 | A1 |
20090205151 | Fisher et al. | Aug 2009 | A1 |
20090205656 | Nishibayashi et al. | Aug 2009 | A1 |
20090259194 | Pinedjian et al. | Oct 2009 | A1 |
20090270832 | Vancaillie et al. | Oct 2009 | A1 |
20100003067 | Shaw et al. | Jan 2010 | A1 |
20100004510 | Kuroshima | Jan 2010 | A1 |
20100047123 | Solomon et al. | Feb 2010 | A1 |
20100049170 | Solomon et al. | Feb 2010 | A1 |
20100050351 | Colantonio et al. | Mar 2010 | A1 |
20100059474 | Brandenburger et al. | Mar 2010 | A1 |
20100064456 | Ferlic | Mar 2010 | A1 |
20100152670 | Low | Jun 2010 | A1 |
20100160894 | Julian et al. | Jun 2010 | A1 |
20100172794 | Ferlic et al. | Jul 2010 | A1 |
20100242993 | Hoang et al. | Sep 2010 | A1 |
20100253070 | Cheon et al. | Oct 2010 | A1 |
20100292673 | Korogi et al. | Nov 2010 | A1 |
20100306938 | Rogers et al. | Dec 2010 | A1 |
20110030726 | Vaillancourt et al. | Feb 2011 | A1 |
20110044850 | Solomon et al. | Feb 2011 | A1 |
20110046564 | Zhong | Feb 2011 | A1 |
20110046603 | Felsovalyi et al. | Feb 2011 | A1 |
20110062703 | Lopez | Mar 2011 | A1 |
20110064512 | Shaw et al. | Mar 2011 | A1 |
20110082431 | Burgess et al. | Apr 2011 | A1 |
20110217212 | Solomon et al. | Sep 2011 | A1 |
20110232020 | Rogers et al. | Sep 2011 | A1 |
20110265825 | Rogers et al. | Nov 2011 | A1 |
20110277788 | Rogers et al. | Nov 2011 | A1 |
20110290799 | Anderson et al. | Dec 2011 | A1 |
20110311602 | Mills et al. | Dec 2011 | A1 |
20110314619 | Schweikert | Dec 2011 | A1 |
20120031904 | Kuhn et al. | Feb 2012 | A1 |
20120039764 | Solomon et al. | Feb 2012 | A1 |
20120157965 | Wotton et al. | Jun 2012 | A1 |
20120191067 | Chia et al. | Jul 2012 | A1 |
20120195807 | Ferlic | Aug 2012 | A1 |
20120216359 | Rogers et al. | Aug 2012 | A1 |
20120216360 | Rogers et al. | Aug 2012 | A1 |
20120283693 | Anderson et al. | Nov 2012 | A1 |
20120283696 | Cronenberg et al. | Nov 2012 | A1 |
20120296284 | Anderson et al. | Nov 2012 | A1 |
20120302970 | Tennican | Nov 2012 | A1 |
20120302997 | Gardner et al. | Nov 2012 | A1 |
20130030414 | Gardner et al. | Jan 2013 | A1 |
20130035667 | Anderson et al. | Feb 2013 | A1 |
20130053751 | Holtham | Feb 2013 | A1 |
20130072908 | Solomon et al. | Mar 2013 | A1 |
20130085313 | Fowler et al. | Apr 2013 | A1 |
20130098398 | Kerr et al. | Apr 2013 | A1 |
20130098938 | Efthimiadis | Apr 2013 | A1 |
20130123754 | Solomon et al. | May 2013 | A1 |
20130171030 | Ferlic et al. | Jul 2013 | A1 |
20130183635 | Wilhoit | Jul 2013 | A1 |
20130274686 | Ziebol et al. | Oct 2013 | A1 |
20140034540 | Solomon et al. | Feb 2014 | A1 |
20140048079 | Gardner et al. | Feb 2014 | A1 |
20140052074 | Tekeste | Feb 2014 | A1 |
20140101876 | Rogers et al. | Apr 2014 | A1 |
20140148781 | Tekeste | May 2014 | A1 |
20140155868 | Nelson et al. | Jun 2014 | A1 |
20140227144 | Liu et al. | Aug 2014 | A1 |
20140228809 | Wong | Aug 2014 | A1 |
20150018774 | Anderson et al. | Jan 2015 | A1 |
20150165127 | Haefele et al. | Jun 2015 | A1 |
20150217106 | Banik et al. | Aug 2015 | A1 |
20150237854 | Mills et al. | Aug 2015 | A1 |
20150238703 | Glocker | Aug 2015 | A1 |
20150258324 | Chida et al. | Sep 2015 | A1 |
20150314119 | Anderson et al. | Nov 2015 | A1 |
20150314120 | Gardner et al. | Nov 2015 | A1 |
20150320926 | Fitzpatrick et al. | Nov 2015 | A1 |
20150374968 | Solomon et al. | Dec 2015 | A1 |
20160001058 | Ziebol et al. | Jan 2016 | A1 |
20160015931 | Ryan et al. | Jan 2016 | A1 |
20160015959 | Solomon et al. | Jan 2016 | A1 |
20160045629 | Gardner et al. | Feb 2016 | A1 |
20160067365 | Ma et al. | Mar 2016 | A1 |
20160067471 | Ingram et al. | Mar 2016 | A1 |
20160088995 | Ueda et al. | Mar 2016 | A1 |
20160089530 | Sathe | Mar 2016 | A1 |
20160101276 | Tekeste | Apr 2016 | A1 |
20160106969 | Neftel | Apr 2016 | A1 |
20160121097 | Steele | May 2016 | A1 |
20160144118 | Solomon et al. | May 2016 | A1 |
20160158520 | Ma et al. | Jun 2016 | A1 |
20160158521 | Hoang et al. | Jun 2016 | A1 |
20160158522 | Hoang et al. | Jun 2016 | A1 |
20160184527 | Tekeste | Jun 2016 | A1 |
20160213912 | Daneluzzi | Jul 2016 | A1 |
20160250420 | Maritan et al. | Sep 2016 | A1 |
20170143447 | Rogers et al. | May 2017 | A1 |
20170203092 | Ryan et al. | Jul 2017 | A1 |
20170239443 | Abitabilo et al. | Aug 2017 | A1 |
20170361023 | Anderson et al. | Dec 2017 | A1 |
20180369562 | Gardner | Dec 2018 | A1 |
20190038888 | Gardner | Feb 2019 | A1 |
20190282795 | Fangrow | Sep 2019 | A1 |
Number | Date | Country |
---|---|---|
2 148 847 | Dec 1995 | CA |
2 169 689 | Aug 1996 | CA |
2 583 601 | Apr 2006 | CA |
2 626 864 | May 2007 | CA |
2 651 192 | Nov 2007 | CA |
2 615 146 | Jun 2008 | CA |
2402327 | Oct 2000 | CN |
2815392 | Sep 2006 | CN |
201150420 | Nov 2008 | CN |
201519335 | Jul 2010 | CN |
89 06 628 | Sep 1989 | DE |
29617133 | Jan 1997 | DE |
0 108 785 | May 1984 | EP |
0 227 219 | Jul 1987 | EP |
0 245 872 | Nov 1987 | EP |
0 639 385 | Feb 1995 | EP |
0 769 265 | Apr 1997 | EP |
1 061 000 | Oct 2000 | EP |
1 331 020 | Jul 2003 | EP |
1 977 714 | Oct 2008 | EP |
2 444 117 | Apr 2012 | EP |
2 606 930 | Jun 2013 | EP |
2 493 149 | May 1982 | FR |
2 782 910 | Mar 2000 | FR |
123221 | Feb 1919 | GB |
2 296 182 | Jun 1996 | GB |
2 333 097 | Jul 1999 | GB |
2 387 772 | Oct 2003 | GB |
57-131462 | Aug 1982 | JP |
04-99950 | Feb 1992 | JP |
09-216661 | Aug 1997 | JP |
2000-157630 | Jun 2000 | JP |
2002-234567 | Aug 2002 | JP |
2002-291906 | Oct 2002 | JP |
2006-182663 | Jul 2006 | JP |
2014-117461 | Jun 2014 | JP |
2 246 321 | Feb 2005 | RU |
WO 198303975 | Nov 1983 | WO |
WO 198505040 | Nov 1985 | WO |
WO 199812125 | Mar 1998 | WO |
WO 2004035129 | Apr 2004 | WO |
WO 2004112846 | Dec 2004 | WO |
WO 2006007690 | Jan 2006 | WO |
WO 2006044236 | Apr 2006 | WO |
WO 2007056773 | May 2007 | WO |
WO 2007137056 | Nov 2007 | WO |
WO 2008042285 | Apr 2008 | WO |
WO 2008086631 | Jul 2008 | WO |
WO 2008089196 | Jul 2008 | WO |
WO 2008100950 | Aug 2008 | WO |
WO 2008140807 | Nov 2008 | WO |
WO 2009002474 | Dec 2008 | WO |
WO 2009117135 | Sep 2009 | WO |
WO 2009123709 | Oct 2009 | WO |
WO 2009136957 | Nov 2009 | WO |
WO 2009153224 | Dec 2009 | WO |
WO 2010002757 | Jan 2010 | WO |
WO 2010002808 | Jan 2010 | WO |
WO 2010034470 | Apr 2010 | WO |
WO 2010039171 | Apr 2010 | WO |
WO 2011028722 | Mar 2011 | WO |
WO 2011053924 | May 2011 | WO |
WO 2011119021 | Sep 2011 | WO |
WO 2012162006 | Nov 2012 | WO |
WO 2012184716 | Dec 2013 | WO |
WO 2013192574 | Dec 2013 | WO |
WO 2014140949 | Sep 2014 | WO |
WO 2015119940 | Aug 2015 | WO |
WO 2015120336 | Aug 2015 | WO |
WO 2015168677 | Nov 2015 | WO |
WO 2017127364 | Jul 2017 | WO |
WO 2017127365 | Jul 2017 | WO |
WO 2018009653 | Jan 2018 | WO |
WO 2018071717 | Apr 2018 | WO |
WO 2018237090 | Dec 2018 | WO |
WO 2018237122 | Dec 2018 | WO |
WO 2019178560 | Sep 2019 | WO |
Entry |
---|
BD Nexvia Closed IV Catheter System, http://www.bd.com/infusion/products/ivcatheters/nexiva/index.asp, downloaded Sep. 6, 2013 in 19 pages. |
Charney, “Baxter Healthcare InterlinkTM IV Access System” in 1 page, from Handbook of Modern Hospital Safety. Published Mar. 1999. |
ICU Medical Inc., “Oncology System Solutions,” Product Brochure in 17 pages, Copyright 2013. |
ICU Medical Inc., “Protective Cap,” Photographs of Spiros Protective Cap in 2 pages, Product available 2013. |
Australian Examination Report re AU Applicaton No. 2008269133, dated Aug. 27, 2012 (4 pages). |
Australian Examination Report (No. 2) re AU Applicaton No. 2008269133, dated Jan. 9, 2013 (3 pages). |
Australian Examination Report (No. 3) re AU Applicaton No. 2008269133, dated May 1, 2013 (3 pages). |
Australian Examination Report (Notice of Acceptance) re AU Applicaton No. 2008269133, dated Nov. 14, 2013 (2 pages). |
Australian Examination Report re AU Applicaton No. 2012258435, dated Apr. 18, 2013 (4 pages). |
Australian Examination Report re AU Applicaton No. 2013100345, dated Apr. 18, 2013 (4 pages). |
Australian Examination Report re AU Application No. 2013224680, dated May 19, 2015 (2 pages). |
Baxter Minicap: Photographs of the Baxter Minicap (Sep. 1, 1998) (4 pages). |
Baxter, “Peritoneal Dialysis Patient Connectology,” Product Descriptions in 1 page, downloaded Jul. 1, 2011. |
Canadian Examination Report, re CA Application No. 2,692,157, dated Apr. 27, 2011 (2 pages). |
Canadian Examination Report, re CA Application No. 2,692,157, dated Jun. 6, 2011 (2 pages). |
Canadian Examination Report, re CA Application No. 2,692,157, dated Jan. 23, 2013 (4 pages). |
Canadian Notice of Allowance, re CA Application No. 2,692,157, dated Oct. 2, 2013 (4 pages). |
Canadian Examination Report, re CA Application No. 2,846,145, dated Apr. 30, 2015 (3 pages). |
Catheter Connections, “Introducing DualCap,” Product Brochure in 1 page, Copyright 2011. |
Chinese Office Action, re CN Application No. 200880103854.5, dated Aug. 3, 2011 (5 pages). |
Chinese Second Office Action, re CN Application No. 200880103854.5, dated Apr. 16, 2012 (4 pages). |
Chinese Third Office Action, re CN Application No. 200880103854.5, dated Nov. 1, 2012 (4 pages). |
Chinese Office Action, re CN Application No. 201310087320.0, dated May 4, 2014 (20 pages). |
Colombian Office Action, re CO Application No. 10.000.937, dated Oct. 2012 (9 pages). |
Colombian Office Action, re CO Application No. 14.094.083, dated Jul. 2015 (13 pages). |
Conical Fittings: International Standard, “Conical fittings with 6% (Luer) Taper for Syringes, Needles and certain Other Medical Equipment—Part 2: Lock Fittings”, Ref. No. ISO 594-2:1998. International Organization for Standardization (Sep. 1, 1998) 2nd ed. (16 pages). |
Devine, Redacted version of letter from David A. Divine, Esq. of Lee & Hayes, dated May 16, 2011 (3 pages). |
Devine, Redacted version of letter from David A. Divine, Esq. of Lee & Hayes, dated May 27, 2011 (3 pages). |
Hospira, “You Work in Neverland,” Lifeshield Product Brochure in 2 pp., Published 2009. |
Hyprotek, “Port Protek,” Product Brochure in 1 pages, downloaded Sep. 19, 2011 from http://www.hyprotek.com/products.html. |
International Written Opinion re PCT/US08/07797, dated Sep. 11, 2008 (3 pages). |
International Preliminary Report on Patentability re PCT/US08/07797, dated Dec. 22, 2009 (4 pages). |
International Search Report re PCT/US2012/037772, dated Oct. 26, 2012 (5 pages). |
International Written Opinion re PCT/US2012/037772, dated Oct. 26, 2012 (5 pages). |
International Preliminary Report on Patentability re PCT/US2012/037772, dated Nov. 26, 2012 (7 pages). |
International Search Report re PCT/US2012/038880, dated Nov. 19, 2012 (5 pages). |
International Written Opinion re PCT/US2012/038880, dated Nov. 19, 2012 (8 pages). |
International Preliminary Report on Patentability re PCT/US2012/038880, dated Nov. 20, 2013 (1 pages). |
International Search Report re PCT/US2012/062078, dated Feb. 14, 2013 (3 pages). |
International Written Opinion re PCT/US2012/062078, dated Feb. 14, 2013 (3 pages). |
International Preliminary Report on Patentability re PCT/US2012/062078, dated May 6, 2014 (3 pages). |
International Search Report re PCT/US2014/23140, dated Jul. 28, 2014 (3 pages). |
International Written Opinion re PCT/US2014/23140, dated Jul. 28, 2014 (6 pages). |
Japanese Office Action, re Jp Application No. 2013-162527, dated Nov. 21, 2014 (2 pages). |
Japanese Final Office Action, re JP Application No. 2010-163450, dated Apr. 3, 2015 (9 pages). |
Menyhay et al., “Disinfection of Needleless Catheter Connectors and Access Ports with Alcohol May Not Prevent Microbial Entry: The Promise of a Novel Antiseptic-Barrier Cap” Infection Control Hospital and Epidemology, vol. 27, No. 1 (Jan. 2006) (5 pages). |
Mexican Office Action (Memo [2nd] concerning OA) re MX Application No. MX/a/2010/000171, dated Oct. 22, 2013 (1 pages). |
Mexican Office Action (Memo concerning OA) re MX Application No. MX/a/2010/000171, dated Feb. 25, 2013 (2 pages). |
New Zealand Examination Report and Notice of Acceptance, re NZ Application No. 582395, dated Jun. 13, 2011 (2 pages). |
New Zealand Examination Report, re NZ Application No. 582395, dated Nov. 8, 2012 (2 pages). |
New Zealand Examination Report and Notice of Acceptance, re NZ Application No. 582395, dated Dec. 5, 2012 (1 page). |
New Zealand Examination Report re NZ Application No. 603404, dated Nov. 8, 2012 (2 pages). |
New Zealand Examination Report (1st) re NZ Application No. 623139, dated Apr. 8, 2014 (1 pages). |
New Zealand Examination Report (1st) re NZ Application No. 623141, dated Apr. 9, 2014 (1 pages). |
New Zealand Examination Report (1st) re NZ Application No. 624449, dated Dec. 5, 2014 (2 pages). |
Photographs of the Baxter Minicap (Sep. 1, 1998) (4 pages). |
U.S. Office Action, re U.S. Appl. No. 11/821,190, dated Dec. 17, 2009 (10 pages). |
U.S. Office Action, re U.S. Appl. No. 11/821,190, dated Aug. 2, 2010 (14 pages). |
U.S. Interview Summary, re U.S. Appl. No. 11/821,190, dated Nov. 18, 2010 (4 pages). |
U.S. Office Action, re U.S. Appl. No. 11/821,190, dated Mar. 7, 2011 (16 pages). |
U.S. Office Action/Notice of Allowance, re U.S. Appl. No. 11/821,190, dated Apr. 26, 2011 (9 pages). |
U.S. Notice of Allowance, re U.S. Appl. No. 11/821,190, dated Jul. 29, 2011 (6 pages). |
U.S. Office Action, re U.S. Appl. No. 12/214,526, dated Jun. 9, 2011 (7 pages). |
U.S. Final Office Action, re U.S. Appl. No. 12/214,526, dated Oct. 31, 2011 (8 pages). |
U.S. Interview Summary, re U.S. Appl. No. 12/214,526, dated Mar. 23, 2012 (3 pages). |
U.S. Office Action, re U.S. Appl. No. 13/095,516, dated Dec. 21, 2011 (27 pages). |
U.S. Office Action/Notice of Allowance, re U.S. Appl. No. 13/095,516, dated May 16, 2012 (18 pages). |
U.S. Office Action/Non-Final, re U.S. Appl. No. 13/113,777, dated Dec. 3, 2013 (13 pages). |
U.S. Office Action/Final, re U.S. Appl. No. 13/113,777, dated Aug. 25, 2014 (9 pages). |
U.S. Office Action/Final, re U.S. Appl. No. 13/113,777, dated Apr. 3, 2015 (9 pages). |
U.S. Office Action, re U.S. Appl. No. 13/288,529, dated Apr. 8, 2015 (12 pages). |
U.S. Office Action/Non-Final, re U.S. Appl. No. 13/456,853, dated Dec. 14, 2012 (16 pages). |
U.S. Office Action/Final, re U.S. Appl. No. 13/456,853, dated Aug. 27, 2013 (18 pages). |
U.S. Office Action, re U.S. Appl. No. 13/456,853, dated Mar. 27, 2014 (14 pages). |
U.S. Office Action/Notice of Allowance, re U.S. Appl. No. 13/456,853, dated Dec. 3, 2014 (9 pages). |
U.S. Office Action, re U.S. Appl. No. 13/473,057, dated Feb. 8, 2013 (20 pages). |
U.S. Office Action/Final, re U.S. Appl. No. 13/473,057, dated Dec. 3, 2013 (19 pages). |
U.S. Office Action, re U.S. Appl. No. 13/476,722, dated Jun. 24, 2015 (10 pages). |
U.S. Office Action, re U.S. Appl. No. 13/547,650, dated Jan. 29, 2015 (9 pages). |
U.S Office Action, re U.S. Appl. No. 13/560,499, dated Feb. 11, 2015 (9 pages). |
U.S. Office Action, re U.S. Appl. No. 13/649,569, dated May 3, 2013 (15 pages). |
U.S. Office Action/Final, re U.S. Appl. No. 13/649,569, dated Aug. 23, 2013 (19 pages). |
U.S. Office Action, re U.S. Appl. No. 13/649,569, dated Apr. 14, 2014 (27 pages). |
U.S. Office Action, re U.S. Appl. No. 13/649,569, dated Jan. 29, 2015 (14 pages). |
U.S. Office Action, re U.S. Appl. No. 13/649,569, dated Sep. 28, 2015 (17 pages). |
Number | Date | Country | |
---|---|---|---|
20190111245 A1 | Apr 2019 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13803289 | Mar 2013 | US |
Child | 16162106 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13113777 | May 2011 | US |
Child | 13803289 | US |